

Feladilimab Biosimilar - Research Grade

Product Code: ICH6018

More Information

Species Reactivity: Human

Target: ICOS

Concentration: 1.0 - 5.0 mg/ml

Isotype: Human IgG4

Host: CHO

product name H2: Feladilimab Biosimilar - Research Grade

Antibodies against the same target: [Anti-CD278 \(7E.17G9\) In Vivo Antibody - Low Endotoxin \(ICH1082\)](#), [Alomfilimab Biosimilar - Research Grade \(ICH5338\)](#), [Vopratelimab Biosimilar - Research Grade \(ICH5991\)](#)

Aggregation: Aggregation level $\leq$ 5%

Sequence: IMGT

Buffer: ICH3002

UniProt: Q9Y6W8

Shipping Conditions: Blue ice

background: ICH6018 is a research-grade biosimilar of feladilimab (GSK3359609), supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It reproduces the binding specificity of feladilimab, a humanized IgG4 monoclonal directed against the inducible T-cell costimulator (ICOS/CD278), and is intended for in-vitro and functional investigation rather than clinical application. The originator was developed as an ICOS agonist immuno-oncology candidate designed to costimulate ICOS-expressing effector T cells while potentially depleting or modulating ICOS-high regulatory T cells within the tumor microenvironment. This biosimilar is produced to in-vivo research standards with

low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and is available in bulk milligram-to-gram quantities, supporting reproducible experiments and cross-study consistency. As a human IgG4 anti-human ICOS reagent, it is well suited to binding characterization, receptor-engagement assays, competition and epitope studies, and as a matched isotype-format control or reference standard. It provides a defined, cost-effective alternative to therapeutic material for mechanistic and screening work. Content is provided for ichor.bio to review. ICOS (Inducible T-cell COStimulator; CD278; UniProt Q9Y6W8) is a CD28-family costimulatory receptor expressed on activated CD4+ and CD8+ T cells and constitutively at high levels on regulatory T cells. Engagement by its ligand ICOSL (B7-H2/CD275) delivers a costimulatory signal through PI3K and downstream pathways that promotes T-cell activation, proliferation, cytokine production, T follicular helper cell differentiation, and germinal center B-cell responses. In the tumor microenvironment ICOS is often enriched on intratumoral regulatory T cells, making it a dual-edged immuno-oncology target: agonism can amplify effector T-cell function, while ICOS-high Treg populations may be preferentially engaged. This biology motivated development of ICOS agonist antibodies such as feladilimab, which aim to enhance antitumor immunity through costimulation and modulation of the ICOS/ICOSL axis.

Other names: Activation-inducible lymphocyte immunomediatory molecule, Inducible T-cell costimulator, AILIM

Purification Method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation: This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Purity: >95% by SDS-PAGE

Endotoxin: 1.0 EU/mg as determined by the LAL method

Storage: This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Applications: Functional Assays



Application Notes: Each investigator should determine their own optimal working dilution for specific applications.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.